US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

28.71

+0.06000.21%

Volume:288

Turnover:8.27K

Market Cap:2.58M

PE:- -

High:28.78

Open:28.78

Low:28.71

Close:28.65

52wk High:29.89

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:0.86

T/O Rate:0.32%

Dividend:0.92

Dividend Rate:3.20%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Ultragenyx price target raised to $35 from $32 at Barclays

Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

Asep Medical Settles $288,500 in Debt Through Share Issuance

Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide

Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111

Ultragenyx confirms FDA approval of Fayuvi

Longeveron Stock (LGVN) Plummets 56% on a Failed Clinical Trial

Hemab Therapeutics doses first patient in HMB-003 trial

Nuvation Bio announces FDA approval of sNDA for Ibtrozi

Fennec presents results from STS-J01 clinical trial evaluating Pedmark

Rakovina Therapeutics Adds Yale DNA Repair Expert to Scientific Advisory Board

Bayer receives FDA approval for Kerendia for CKD with type 1 diabetes

Guizhou Bailing Unit Gets China Regulator's Nod to Trial Tangning Tongluo Cream

MT Newswires Live

Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial

Optimi Health to Launch Phase 3 MDMA Trial for PTSD in Veterans and Frontline Workers

Hansoh Pharma Wins NMPA Nod for Clinical Trials of Innovative Cancer Drug HS-20197

TME Pharma CEO Emphasizes Cash Discipline and Strategic Partnering for Lead Cancer Asset

ASX biotech expands diagnostics portfolio after FDA approval

Morning Star AU

Arrowhead announces interim topline data from Phase 1/2a trial of ARO-DIMER-PA

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/NVIB/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":28.711,"timestamp":1791566858836,"preClose":28.651,"halted":0,"volume":288,"delay":0,"changeRate":0.0020941677428361564,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Trading","change":0.06,"latestTime":"10-09 13:37:58 EDT","open":28.775,"high":28.775,"low":28.711,"amount":8266.601088,"amplitude":0.002234,"askPrice":28.56,"askSize":100,"bidPrice":28.49,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791576000000},"marketStatusCode":2,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":28.651,"nav":29.611,"aum":2664977.22,"dividendRate":0.031981,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":29.6504,"preClose":28.651,"latestTime":"16:10 EDT","volume":6,"amount":171.906,"timestamp":1791490204365,"change":0.9994,"changeRate":0.034882,"amplitude":0},"volumeRatio":0.858421},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.858421,"shares":90001,"dividePrice":0.9182,"high":28.775,"amplitude":0.002234,"preClose":28.651,"low":28.711,"week52Low":24.54,"pbRate":"--","week52High":29.89,"institutionHeld":0,"latestPrice":28.711,"eps":0,"divideRate":0.031981,"volume":288,"delay":0,"ttmEps":0,"open":28.775,"prevYearClose":25,"prevWeekClose":29.1392,"prevMonthClose":28.4278,"prevQuarterClose":28.4278,"fiveDayClose":29.1392,"twentyDayClose":27.3696},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-09-30","symbol":"NVIB","amount":0.23782,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-30","defaultRemindTime":1790775000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-01","payableDate":"2026-09-30","currency":"USD","dateTimestamp":1790740800000,"payDate":"2026-10-01"},{"date":"2026-09-15","symbol":"NVIB","amount":0.22766,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-16","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-16"},{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"},{"executeDate":"2026-09-15","recordDate":"2026-09-15","paymentDate":"2026-09-16","value":0.22766,"currency":"USD"},{"executeDate":"2026-09-30","recordDate":"2026-09-30","paymentDate":"2026-10-01","value":0.23782,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669442151","title":"Ultragenyx price target raised to $35 from $32 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2669442151","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669442151?lang=en_us&edition=fundamental","pubTime":"2026-09-21 17:10","pubTimestamp":1789981807,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Ultragenyx (RARE) to $35 from $32 and keeps an Overweight rating on the shares following FDA approval of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ultragenyx-price-target-raised-to-35-from-32-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ultragenyx-price-target-raised-to-35-from-32-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","MRNX","GDOC","IYH","FRTY","IEIH","LFSC","BK4139","TECB","MEDI","NVIB","TBXU","LABU","SYNB","RSPH","IDNA","GNMX","PINK","PSCH","MRNY","BMED","RARE","BK4588","BBP","XLVX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668318487","title":"Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2668318487","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668318487?lang=en_us&edition=fundamental","pubTime":"2026-09-20 22:15","pubTimestamp":1789913705,"startTime":"0","endTime":"0","summary":"Cue Biopharma (CUE) announced positive topline results from the Phase 2 clinical trial of CUE-221 conducted in China by Genesis Life Sciences, a re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cue-biopharma-announces-phase-2-trial-of-cue-221-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cue-biopharma-announces-phase-2-trial-of-cue-221-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","BBC","CUE","BK4139","PSIL","NVIB","HYLG","IDNA","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668186624","title":"Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria","url":"https://stock-news.laohu8.com/highlight/detail?id=2668186624","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668186624?lang=en_us&edition=fundamental","pubTime":"2026-09-20 18:00","pubTimestamp":1789898400,"startTime":"0","endTime":"0","summary":"Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling studyPrimary endpoint and the key secondary e","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/20/3365072/0/en/cue-biopharma-announces-positive-topline-results-from-cue-221-phase-2-study-in-chronic-spontaneous-urticaria.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","GDOC","IDNA","NVIB","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668043976","title":"Asep Medical Settles $288,500 in Debt Through Share Issuance","url":"https://stock-news.laohu8.com/highlight/detail?id=2668043976","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668043976?lang=en_us&edition=fundamental","pubTime":"2026-09-19 07:02","pubTimestamp":1789772544,"startTime":"0","endTime":"0","summary":"The latest update is out from ASEP Medical Holdings Inc ( ($TSE:ASEP) ). Asep Medical Holdings Inc., a biotech-focused investment issuer based in V...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/asep-medical-settles-288500-in-debt-through-share-issuance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/asep-medical-settles-288500-in-debt-through-share-issuance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668973580","title":"Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide","url":"https://stock-news.laohu8.com/highlight/detail?id=2668973580","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668973580?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:05","pubTimestamp":1789761914,"startTime":"0","endTime":"0","summary":"Amneal Pharmaceuticals (AMRX) “announced that the U.S. Food and Drug Administration has approved its lanreotide injection, 120 mg/0.5 mL, in a ster...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amneal-pharmaceuticals-announces-fda-approval-and-launch-of-lanreotide-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amneal-pharmaceuticals-announces-fda-approval-and-launch-of-lanreotide-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLVX","GDOC","PSCH","SYNB","PINK","MRNY","NVIB","BK4007","BMED","LABU","LFSC","IEIH","TBXU","IBB","IYH","IDNA","BK4588","GNMX","MRNX","BK4585","RSPH","FRTY","MEDI","TECB","AMRX","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668282679","title":"Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111","url":"https://stock-news.laohu8.com/highlight/detail?id=2668282679","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668282679?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:35","pubTimestamp":1789731320,"startTime":"0","endTime":"0","summary":"Abeona Therapeutics (ABEO) “congratulated” Ultragenyx Pharmaceutical (RARE) on the U.S. Food and Drug Administration, FDA, approval of FAYUVI, also...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abeona-therapeutics-congratulated-ultragenyx-on-u-s-fda-approval-of-ux111-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abeona-therapeutics-congratulated-ultragenyx-on-u-s-fda-approval-of-ux111-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABEO","PINK","IEIH","RSPH","IDNA","LABU","MRNX","GNMX","NVIB","TECB","MEDI","FRTY","SYNB","XLVX","PSCH","BK4585","GDOC","MRNY","BMED","BBP","LFSC","IBB","BK4139","TBXU","IYH","RARE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668994030","title":"Ultragenyx confirms FDA approval of Fayuvi","url":"https://stock-news.laohu8.com/highlight/detail?id=2668994030","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668994030?lang=en_us&edition=fundamental","pubTime":"2026-09-18 03:55","pubTimestamp":1789674924,"startTime":"0","endTime":"0","summary":"Ultragenyx (RARE) announced that the U.S. FDA granted standard full approval of Fayuvi, also known as UX111, for the treatment of pediatric patient...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ultragenyx-confirms-fda-approval-of-fayuvi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ultragenyx-confirms-fda-approval-of-fayuvi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IYH","IEIH","BBP","MRNY","MEDI","TECB","BK4588","RARE","MRNX","SYNB","LABU","FRTY","PINK","LFSC","XLVX","IBB","BK4585","TBXU","BMED","IDNA","PSCH","GDOC","RSPH","NVIB","BK4139","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668999169","title":"Longeveron Stock (LGVN) Plummets 56% on a Failed Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2668999169","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668999169?lang=en_us&edition=fundamental","pubTime":"2026-09-18 00:44","pubTimestamp":1789663452,"startTime":"0","endTime":"0","summary":"Longeveron stock took a 56.14% beating on Thursday after the company posted a failed clinical trial.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/longeveron-stock-lgvn-plummets-56-on-a-failed-clinical-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/longeveron-stock-lgvn-plummets-56-on-a-failed-clinical-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","MEDX","LGVN","HYLG","NVIB","BK4139","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668196234","title":"Hemab Therapeutics doses first patient in HMB-003 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2668196234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668196234?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:05","pubTimestamp":1789646751,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics (COAG) announced that the first healthy volunteer has been dosed in its Phase 1 clinical trial evaluating HMB-003, an investigat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hemab-therapeutics-doses-first-patient-in-hmb-003-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hemab-therapeutics-doses-first-patient-in-hmb-003-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","GDOC","LENZ","IDNA","MEDX","BK4139","HYLG","BK4539","COAG","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668996120","title":"Nuvation Bio announces FDA approval of sNDA for Ibtrozi","url":"https://stock-news.laohu8.com/highlight/detail?id=2668996120","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668996120?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:35","pubTimestamp":1789644932,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) announced that the U.S. FDA has approved a supplemental New Drug Application for Ibtrozi, a ROS1 inhibitor approved for the tre...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvation-bio-announces-fda-approval-of-snda-for-ibtrozi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvation-bio-announces-fda-approval-of-snda-for-ibtrozi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PINK","IEIH","MRNX","TECB","MEDI","GDOC","NVIB","RSPH","BMED","IDNA","FRTY","GNMX","LABU","LFSC","PSCH","SYNB","NUVB","MRNY","IBB","TBXU","BK4585","XLVX","BK4007","BK4588","BBP","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668196173","title":"Fennec presents results from STS-J01 clinical trial evaluating Pedmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2668196173","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668196173?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:35","pubTimestamp":1789644911,"startTime":"0","endTime":"0","summary":"Fennec (FENC) announced the oral presentation of detailed results from the investigator-initiated Phase 2 STS-J01 clinical trial evaluating Pedmark...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fennec-presents-results-from-sts-j01-clinical-trial-evaluating-pedmark-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fennec-presents-results-from-sts-j01-clinical-trial-evaluating-pedmark-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FENC","BK4139","IDNA","NVIB","HYLG","MEDX","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668963402","title":"Rakovina Therapeutics Adds Yale DNA Repair Expert to Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2668963402","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668963402?lang=en_us&edition=fundamental","pubTime":"2026-09-17 17:32","pubTimestamp":1789637575,"startTime":"0","endTime":"0","summary":"Rakovina Therapeutics Inc ( ($TSE:RKV) ) just unveiled an announcement. Rakovina Therapeutics has appointed Yale physician-scientist and biotech en...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rakovina-therapeutics-adds-yale-dna-repair-expert-to-scientific-advisory-board?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rakovina-therapeutics-adds-yale-dna-repair-expert-to-scientific-advisory-board?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","XBIX","NVIB","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668963474","title":"Bayer receives FDA approval for Kerendia for CKD with type 1 diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2668963474","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668963474?lang=en_us&edition=fundamental","pubTime":"2026-09-17 17:30","pubTimestamp":1789637420,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) announced that theFDA approved Kerendia to reduce urinary albumin-to-creatinine ratio, which is expected to reduce the risk of sustai...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-receives-fda-approval-for-kerendia-for-ckd-with-type-1-diabetes-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-receives-fda-approval-for-kerendia-for-ckd-with-type-1-diabetes-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","SYNB","IEIH","FRTY","LABU","TBXU","BBP","BMED","NVIB","MEDI","BK4007","PSCH","GDOC","IYH","GNMX","IBB","BAYRY","PINK","XLVX","TECB","MRNY","LFSC","IDNA","MRNX","BK4588","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668959271","title":"Guizhou Bailing Unit Gets China Regulator's Nod to Trial Tangning Tongluo Cream","url":"https://stock-news.laohu8.com/highlight/detail?id=2668959271","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668959271?lang=en_us&edition=fundamental","pubTime":"2026-09-17 14:17","pubTimestamp":1789625847,"startTime":"0","endTime":"0","summary":"Bailing Yuxiu  Pharmaceutical, a wholly-owned subsidiary of Guizhou Bailing Group Pharmaceutical , has received approval from China's National Medical Products Administration to conduct clinical trials of Tangning Tongluo Cream for diabetic foot ulcers, according to a Wednesday filing with the Shenzhen bourse.Tangning Tongluo is a traditional Chinese medicine drug available in tablet and cream formulations for diabetes-related conditions.The clinical trial application was approved subject to further refinement of the trial protocol.In November 2024, the company received NMPA approval to conduct a Phase III clinical trial of Tangning Tongluo tablets for diabetic retinopathy. In October 2025, it received approval to conduct clinical trials of Tangning Tongluo tablets for Type 2 diabetes.The company said the cream could potentially complement its Tangning Tongluo tablets to form an \"oral plus topical\" treatment system.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0077","BK0146","IDNA","BK0183","BK0028","002424","BK0188","GDOC","MEDX","NVIB","HYLG","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668936994","title":"Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2668936994","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668936994?lang=en_us&edition=fundamental","pubTime":"2026-09-17 05:35","pubTimestamp":1789594520,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) announced topline results from ELPIS II, its Phase 2b clinical trial evaluating its investigational stem cell therapy laromestroc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeverons-laromestrocel-did-not-meet-primary-endpoint-in-phase-2b-hlhs-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeverons-laromestrocel-did-not-meet-primary-endpoint-in-phase-2b-hlhs-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","IBBQ","HYLG","IBB","LFSC","IDNA","MEDX","FBT","SYNB","NVIB","LGVN","GNOM","CNCR","BK4585","GDOC","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667840559","title":"Optimi Health to Launch Phase 3 MDMA Trial for PTSD in Veterans and Frontline Workers","url":"https://stock-news.laohu8.com/highlight/detail?id=2667840559","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667840559?lang=en_us&edition=fundamental","pubTime":"2026-09-16 23:38","pubTimestamp":1789573088,"startTime":"0","endTime":"0","summary":"Optimi Health ( ($TSE:OPTI) ) has shared an update. Optimi Health plans to launch a Health Canada-authorized Phase 3 clinical trial in 2027 to eval...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/optimi-health-to-launch-phase-3-mdma-trial-for-ptsd-in-veterans-and-frontline-workers?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/optimi-health-to-launch-phase-3-mdma-trial-for-ptsd-in-veterans-and-frontline-workers?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","MEDX","NVIB","IDNA","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667601377","title":"Hansoh Pharma Wins NMPA Nod for Clinical Trials of Innovative Cancer Drug HS-20197","url":"https://stock-news.laohu8.com/highlight/detail?id=2667601377","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667601377?lang=en_us&edition=fundamental","pubTime":"2026-09-16 17:12","pubTimestamp":1789549943,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Company Limited ( ($HK:3692) ) has issued an announcement. Hansoh Pharmaceutical Group has received clinical trial appr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/hansoh-pharma-wins-nmpa-nod-for-clinical-trials-of-innovative-cancer-drug-hs-20197?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/hansoh-pharma-wins-nmpa-nod-for-clinical-trials-of-innovative-cancer-drug-hs-20197?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","GDOC","NVIB","HYLG","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667089246","title":"TME Pharma CEO Emphasizes Cash Discipline and Strategic Partnering for Lead Cancer Asset","url":"https://stock-news.laohu8.com/highlight/detail?id=2667089246","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667089246?lang=en_us&edition=fundamental","pubTime":"2026-09-16 14:37","pubTimestamp":1789540665,"startTime":"0","endTime":"0","summary":"TME Pharma N.V. ( ($FR:ALTME) ) has provided an announcement. TME Pharma, a clinical-stage biotech group developing therapies for brain cancer and ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tme-pharma-ceo-emphasizes-cash-discipline-and-strategic-partnering-for-lead-cancer-asset?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tme-pharma-ceo-emphasizes-cash-discipline-and-strategic-partnering-for-lead-cancer-asset?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4108","LU0456842615.SGD","NVIB","BK4571","DBB","BK4552","LU0269904917.USD","LU0359202008.SGD","01698","LU1023057109.AUD","IE00BYQNZ168.SGD","TME","IE00BYTNYN87.SGD","IE00B12V2V27.USD","BK4531","BK4548","XBIX","BK4509","LU2039709279.SGD","LU0359201612.USD","BK4526","BK4535","SG9999011746.SGD","LU0828238088.HKD","BK4565","BK4563","BBC","LU0509642566.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667671746","title":"ASX biotech expands diagnostics portfolio after FDA approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2667671746","media":"Morning Star AU","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667671746?lang=en_us&edition=fundamental","pubTime":"2026-09-16 00:00","pubTimestamp":1789488000,"startTime":"0","endTime":"0","summary":"Telix Pharmaceutical’s (ASX.TLX) Pixclara becomes the first positron emission tomography, or PET, imaging agent for glioma brain cancer to receive approval from the US Food and Drug Administration.Why","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"morningstar_stock","url":"https://www.morningstar.com.au/stocks/asx-biotech-expands-diagnostics-portfolio-after-fda-approval","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.morningstar.com.au/stocks/asx-biotech-expands-diagnostics-portfolio-after-fda-approval","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"morningstar_stock","symbols":["XLVX","PINK","PSCH","MRNX","MRNY","IBB","TECB","RSPH","BK4588","GDOC","SYNB","IEIH","BMED","GNMX","XBIX","MEDI","BK4585","IDNA","BBP","IYH","TBXU","FRTY","LABU","NVIB","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667644329","title":"Arrowhead announces interim topline data from Phase 1/2a trial of ARO-DIMER-PA","url":"https://stock-news.laohu8.com/highlight/detail?id=2667644329","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667644329?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:35","pubTimestamp":1789472125,"startTime":"0","endTime":"0","summary":"Arrowhead (ARWR) Pharmaceuticals announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s first investigation...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arrowhead-announces-interim-topline-data-from-phase-1-2a-trial-of-aro-dimer-pa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arrowhead-announces-interim-topline-data-from-phase-1-2a-trial-of-aro-dimer-pa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","ARWR","GDOC","BK4588","BK4585","MEDX","NVIB","HYLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}